Tilak Healthcare is a French digital health company that builds a prescription-only mobile medical platform, OdySight, which combines clinically validated visual tests with gamified interfaces to remotely monitor chronic retinal diseases such as age‑related macular degeneration and diabetic retinopathy, and has been deployed in several European markets with reimbursement in France and documented patient uptake since 2018[2][1][3].
High‑Level Overview
- Mission: To transform management of chronic eye conditions by empowering patients to monitor vision at home while strengthening clinician follow‑up to optimize treatment decisions[2].
- Investment philosophy / Key sectors / Impact on startup ecosystem (if treated as an investment firm): Tilak is not an investment firm but a digital‑health product company focused on ophthalmology and digital therapeutics; it sits at the intersection of mobile gaming, medical devices, and telemedicine and has attracted strategic healthcare and VC investors (Elaia, Cap Horn, iBionext, SWEN, Théa, others) supporting scale‑up and international roll‑out[3][1].
- Product / Customers / Problem / Growth (as a portfolio company): Tilak’s principal product, OdySight, is a CE‑marked mobile app prescribed by ophthalmologists to patients with chronic macular disease to self‑test and transmit visual parameters from home, addressing low adherence to paper tools (Amsler grid), clinic capacity limits, and need for earlier detection of vision deterioration; it has been prescribed thousands of times in Europe (reported ~12–15k prescriptions/patients since launch) and achieved reimbursed status in France, with fundraising to accelerate rollout and product development[1][3][2].
Origin Story
- Founding year and founders: Tilak Healthcare was founded in 2016 by Edouard Gasser (ex‑Gameloft videogame executive) and Professor José‑Alain Sahel (leading retinal specialist and founder of the Vision Institute), combining game design expertise with ophthalmology clinical leadership[2][6].
- How the idea emerged: The founders saw that time spent playing mobile games could be repurposed to engage patients in regular self‑monitoring, so they built OdySight to blend validated visual tests with game mechanics to increase adherence and data quality[2].
- Early traction / pivotal moments: OdySight launched in 2018 and has been prescribed and used by thousands of patients in Europe; the company earned CE marking for the app as a medical device, secured reimbursement pathways (France’s Article 51 experimental funding and eventual reimbursement), and completed multiple funding rounds (including a €10M round to scale in France and abroad), bringing total funding reported in press to the low‑tens of millions to support expansion and new indications[1][3][5].
Core Differentiators
- Clinically validated tests embedded in a gamified UX: OdySight integrates validated visual acuity and scotoma/central field tests inside a game‑like wrapper to improve engagement and measurement frequency versus traditional paper methods[2][1].
- Prescription‑only, regulated medical device pathway: The app is CE‑marked and positioned as a prescription medical device (Class I moving toward Class IIa under MDR), which supports clinical adoption and reimbursement discussions[1][2].
- Reimbursement and payer engagement: Achieved reimbursement in France and participation in governmental experimental schemes, creating an early sustainable commercial model uncommon for many digital therapeutics[3][1].
- Clinical and academic credibility: Co‑founded by a prominent retinal specialist and developed with ophthalmology partners, supporting clinical trials and convergence between at‑home measures and clinic standards[2][5].
- Strategic investor and industry partnerships: Backing from specialized health investors and ophthalmology industry partners (e.g., Laboratoires Théa) helps distribution into clinical channels and international markets[3][5].
Role in the Broader Tech Landscape
- Trend alignment: Tilak rides converging trends in digital therapeutics, remote patient monitoring, regulated mobile health, and gamification for adherence, all accelerated by pressure on healthcare systems and telemedicine adoption[2][3].
- Timing and market forces: Growing prevalence of chronic retinal disease (aging populations, diabetes), clinic capacity constraints, and payer interest in remote monitoring create adoption tailwinds, while regulatory recognition of software‑as‑medical‑device enables commercialization and reimbursement pathways in Europe[2][3][1].
- Influence on ecosystem: By demonstrating a prescription, reimbursed mobile medical game with clinical validation, Tilak serves as a model for how small digital‑health startups can combine UX, regulation, and payer strategy to scale; its partnerships with ophthalmology leaders and industry investors also help legitimize gamified digital therapeutics in specialty care[3][2].
Quick Take & Future Outlook
- What’s next: Expect Tilak to continue international roll‑out (targeting broader European markets and potentially the U.S.), expand indications beyond maculopathies, progress regulatory classification upgrades, and deepen payer and clinical integrations to reach profitability targets cited by management in prior funding communications[3][1].
- Key trends to watch: Regulatory evolution for medical software (MDR and equivalents), reimbursement acceptance of remote monitoring tools, broader teleophthalmology adoption, and competition from other smartphone‑based vision monitoring startups will shape Tilak’s growth trajectory[1][3].
- Potential impact: If Tilak sustains clinical validity, reimbursement, and physician adoption at scale, it could reduce clinic burden through earlier detection of disease reactivation, improve treatment timeliness for sight‑threatening conditions, and set a template for gamified digital therapeutics in other specialties[2][3].
Sources cited above include Tilak’s corporate site and company profiles plus press coverage of funding and clinical deployment; specific claims on founding, product, CE marking, prescriptions/reach, investors and funding rounds are drawn from those sources[2][1][3][5]. If you’d like, I can: pull the latest regulatory status (MDR class), compile clinical‑trial results (TIL002), or prepare a slide‑ready one‑pager summarizing metrics for investor or clinical audiences.
